Trial Profile
Nivolumab in Patients with Previously Treated Advanced Non Small Cell Lung Cancer (NSCLC), second or third Line Nivolumab Versus first Line therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Oct 2018
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Oct 2018 New trial record
- 26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer